NEW YORK, July 26, 2017 /PRNewswire/ --
If you want a Stock Review on ABT, BSX, MDT, or MDXG then come over to http://dailystocktracker.com/register/
North Chicago, Illinois headquartered Abbott Laboratories' shares gained 0.06%, closing Tuesday's trading session at $50.83. The stock recorded a trading volume of 5.68 million shares. The Company's shares have advanced 3.57% in the last month, 16.16% over the previous three months, and 32.34% since the start of this year. The stock is trading 7.73% above its 50-day moving average and 17.69% above its 200-day moving average. Additionally, shares of Abbott Labs, which manufactures and sells health care products worldwide, have a Relative Strength Index (RSI) of 74.75.
On June 29th, 2017, research firm Jefferies resumed its 'Buy' rating on the Company's stock.
On July 13th, 2017, Abbott Labs and Bigfoot Biomedical announced that they have entered into an agreement to develop and commercialize diabetes management systems, integrating the former's FreeStyle® Libre glucose sensing technology with Bigfoot's insulin delivery solutions in the US. This collaboration brings people living with diabetes a significant step closer to the ultimate goal of eliminating much of the daily burden of diabetes management. See our free and comprehensive research report on ABT at:
On Tuesday, shares in Marlborough, Massachusetts headquartered Boston Scientific Corp. recorded a trading volume of 4.47 million shares. The stock declined 0.14%, ending the day at $27.58. The Company's shares have advanced 7.15% in the previous three months and 27.51% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 0.36% and 12.60%, respectively. Furthermore, shares of Boston Scientific, which develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide, have an RSI of 47.97.
On June 28th, 2017, research firm Barclays reiterated its 'Overweight' rating on the Company's stock with an increase of the target price from $30 a share to $31 a share.
On July 05th, 2017, Boston Scientific announced that it will webcast its conference call discussing financial results and business highlights for Q2 ended June 30th, 2017 on July 27th, 2017, at 8:00 a.m. EDT. The Company will also issue a news release announcing Q2 2017 financial results on the same day prior to the conference call. A live webcast of the conference call will be available under the Investor Relations section of the Company's website. BSX free research report is just a click away at:
Dublin, Ireland headquartered Medtronic PLC's stock finished the day 0.99% higher at $85.93. A total volume of 5.24 million shares was traded, which was above their three months average volume of 4.32 million shares. The Company's shares have advanced 5.10% in the previous three months and 20.64% on an YTD basis. The stock is trading above its 200-day moving average by 6.41%. Additionally, shares of Medtronic, which manufactures and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide, have an RSI of 42.76.
On July 11th, 2017, Medtronic announced first enrollments in the STOP AF First clinical trial. The trial will evaluate the safety and effectiveness of performing pulmonary vein isolation with the Arctic Front AdvanceTM Cryoballoon in patients with symptomatic paroxysmal atrial fibrillation prior to treatment with antiarrhythmic medications. The first patient in the trial was recently enrolled at The Ohio State University Wexner Medical Center by Jaret Tyler, M.D. Sign up for your complimentary report on MDT at:
Shares in Marietta, Georgia headquartered MiMedx Group Inc. ended yesterday's session 0.93% lower at $14.87. The stock recorded a trading volume of 450,518 shares. The Company's shares have surged 28.97% over the previous three months and 67.83% since the start of this year. The stock is trading 0.82% and 39.74% above its 50-day and 200-day moving averages, respectively. Moreover, shares of MiMedx, which develops, processes, and markets patent protected and proprietary regenerative biomaterial products and bioimplants processed from human placental tissue, skin, and bone, have an RSI of 50.03.
On July 13th, 2017, MiMedx announced its revenue results for Q2 2017. The Company recorded record revenue of $76.4 million, a $19.1 million or 33% increase over Q2 2016 revenue of $57.3 million. Revenue for the six months ended June 30th, 2017 was $149 million, a $38.3 million, or 35% increase, over revenue for the six months ended June 30th, 2016 of $110.7 million.
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
A prosthetic heart valve is an artificial device surgically implanted into the heart to replace a ...
PUVA or photochemotherapy is used to treat several skin disorders with the help of UV light and the ...
Breathing in unclean air due to increasing air pollution could cause kidney damage with resultant ...View All